Document:

Purchase Contract for FCS, dated as of April 12, 2005

 Exhibit 10.13 
 REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN***. 
 English translation of the executed copy

 PURCHASE CONTRACT 
  

			
	 	 	ORIGINAL

 Contract No. WK20050311SS 
 Date: [    ] 
 Contracting Parties: 
 The Supplier: Shanghai WeiKe Biochemical Reagent Company 
 Address:
        Room 3205, No.172 Yu Yuan Road, Jing’an District, Shanghai 
 The Purchaser: Shenyang Sunshine
Pharmaceutical Co., Ltd. 
 Address:        Jia 3, No. 10 Road, Economic and Technological Development Zone, Shenyang

  

	I.	The Purchaser and the Supply hereby agree after consultation with the purchase and sale of the following items, and enter into the following terms for common observance.

  

													
	 No.
	  	Item Name	  	Specification	  	Lot No.	  	 Quantity
 (bottle)
	  	Unit
Price
(Yuan)	  	Amount
(Yuan)
	 A15-649
	  	FCS-Gold	  	500ml	  	A64904-0050	  	400	  	***	  	***
	 TOTAL RMB (in words): ***
	  		  		  		  		  		  	

  

	II.	Supply Period: 

 Commencing from the day on which this
Contract takes effect and ending on condition that the goods in stipulated quantity are fully delivered. After formal execution of this Contract, the Supplier shall, as required by the Purchaser, arrange for shipment in batches (each shipment not
less than 20 bottles). 
  

	III.	Quality Requirement and Guarantee: 

 The Supplier
guarantees that the items provided hereof are goods within their time of efficacy, and are complying with the manufacturer’s requirement and in standard quality/specification. 
  

	IV.	Location and Method of Delivery: 

 The Supplier shall have
the goods delivered to the address provided by the Purchaser. 
  

 1 

 REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN***. 
  

	V.	Standard and Method of Acceptance Inspection 

 On
inspecting and accepting the goods delivered by the Supplier, the Purchaser shall have the right to refuse acceptance of the goods and have them returned if the packaging of the goods is found damaged. For goods passing the acceptance inspection,
any quality problems found thereafter should be raised in written form within two months with a detailed experiment report. Otherwise, the goods concerned would not be accepted for return and handled, nor compensated by the Supplier. The Purchaser
should have the goods stored and placed and used properly according to the product storage requirements and operation standards provided by the Supplier. The Purchaser shall be liable for any quality problems caused by improper storage or operation.

  

	VI.	Method and Deadline of Settlement: 

 The Purchaser should
settle fully the price of goods in a lump-sum within 30 working days after the day on which the ordered goods are received. 
 Payment Method:
To be settled by transfer of accounts. 
  

	VII.	Force Majeure Accidents: 

 The Supplier shall not be held
liable for the delay in shipment or non-delivery of the goods in consequence of a Force Majeure accident. However, the Supplier shall inform the Purchaser promptly of the occurrence of the accident. In case the accident lasts for more than ten
weeks, the Purchaser shall have the right to revoke this Contract. 
  

	VIII.	Confidentiality: 

 Both parties shall, during and after the
term of this Contract, maintain confidence of all data and information provided and exchanged to each other. No party hereto may disclose or make public without authorization any content in this Contract to a third party. Otherwise, the non-default
party shall have the right to claim against the default party in respect of all the liabilities therefrom. 
  

	IX.	Liability of Default: 

 In case one party fails to perform
any obligation stipulated in this Contract, the other party may claim against the default party for compensation. The details are set out as follows: 
  

	 	9.1	The Supplier shall be held liable for the goods provided by it that are not conform to the requirements provided in this Contract, and the Purchaser shall have the right to require
the Supplier to return or replace the goods within the period mutually agreed by both parties hereto, totally on the expense of the Supplier. Compensation resulting from quality of the products shall be confined to the products concerned, and shall
not involve any other loss. 

  

 2 

 REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN***. 
  

	 	9.2	In case the Purchaser fails to make timely payment as scheduled in this Contract, the Supplier may charge the Purchaser at 0.5% per day as fine for delaying payment of the overdue
price of the goods. 

  

	X.	Completion Terms of this Contract 

 Both parities shall not
alter or revoke this Contract at will during the term of this Contract. For matters not covered hereunder, both parties shall enter into supplementary provisions through mutual consultation. The supplementary provisions and the appendixes hereto are
of the same legal effect as this Contract. This Contract is made in duplicate, with each party holding one copy. This Contract shall take effect after it is signed and sealed by both parties and their authorized representatives. 
  

							
	The Supplier	 		 	The Purchaser	 	
		
	 Company Name (company seal):
 /affixed with
company sealed/
	 	Company Name (company seal):
	Legal Representative:	 		 	Legal Representative:	 	
	Appointed Agent:	 	 /s/ Zhang Xiaojun
	 	Appointed Agent:	 	 /s/ Hu Nai

	 Tel: 021-62490335
 Correspondent Bank: CCB,
Jing’an
 Sub-branch
 Account Number:
05508300020008995
 Postal Code: 200040
 Address: Room 3205,
No.172, Yu
 Yuan Road, Jing’an District, Shanghai
	 	 (12/4/1005)
 Tel: 024-25810471
 Correspondent Bank:
 Account Number:
 Postal Code: 110027
 Address: Jia 3, No. 10 Road, Economic
 and Technological Development Zone, Shenyang

  

 3 

 CONFIDENTIAL TREATMENT 
  

 1Collaboration Agreement, dated as of March 4, 2006

 Exhibit 10.14 
 REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN***. 
 Agreement between Shenyang Sunshine
Pharmaceutical Company and 
 Epitomics, Inc. 
 License and Co-development of anti-TNFalpha monoclonal antibody therapeutics 
 Terms: 
 This term sheet is between Shenyang Sunshine Pharmaceutical Co. Ltd (Sunshine) and Epitomics Inc. (Epitomics). This document is to describe a developing and anticipated
ongoing formal Licensing and Co-development relationship between the two companies in the field of commercializing anti-TNFalpha monoclonal antibodies to be used as therapeutic agents. 
 Background: 
 Anti-TNFalpha therapies account for $6.5B last
year and is expected to grow to $10B by 2010. Anti-TNFalpha therapies are effective in treating Rheumatoid arthritis, Psoriasis, Psoriatic arthritis, Ankylosing spondylis and Crohn’s diseases. Currently, monoclonal antibodies Remicade and
Humira dominate the market. There are several clinical trials for anti-TNFalpha antibodies. 
 Epitomics, Inc. is an emerging biotechnology company that is
dedicated to developing breakthrough monoclonal antibody technology for research, diagnostic and therapeutic applications. The Company utilizes a proprietary and patented technology in the development and production of Rabbit Monoclonal Antibodies
(RabMAb technology). Compared to currently available antibody technologies, this RabMAb technology can generate antibodies more efficiently and ones that have superior binding affinities. Equally, many of the RabMAb antibodies that have been
produced demonstrate bioactivity in a wide variety of biological assays. The Company is headquartered in Burlingame, California, USA and has manufactured more 1,000 monoclonal antibodies with greater than 100 publications utilizing their antibody
platform. Other core capabilities and Intellectual Property surround both the large-scale manufacturing and the humanization of Monoclonal antibodies. 
 Area of Specific Interest for both Parties: 
 Epitomics has developed a panel of 50 novel anti-TNFalpha rabbit monoclonal antibodies
that are highly potent compared with Remicade and Humira in in-vitro assays. Sunshine Pharmaceutical Co. Ltd is one of the largest bio-generic Companies in China. Currently, it has three bio-generic products on the market and has more products in
the pipeline. Sunshine pharmaceutical has the capability of large scale production and clinical development capability. It is anticipated that both parties will bring their respective areas of expertise to the Co-development endeavor in the pursuit
of commercializing the various anti-TNFalpha rabbit monoclonal antibodies and potential other biologically activity compounds. 
  

 1 

 REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN***. 
 License grant: 
 Epitomic grants Sunshine an exclusive, royalty
bearing, non-transferable, perpetual license in the field of Therapeutic usage in order to develop and conduct clinical trials to achieve Chinese FDA (SFDA) approval of the rabbit anti-TNFalpha monoclonal antibody compounds. Under these rights,
Epitomics grants both the manufacturing and distribution rights of anti-TNFalpha monoclonal antibody therapeutics covered under the intellectual properties rights owned by Epitomics. 
 Territory of Commercialization: 
 The territory defined for the Therapeutic rights granted to Sunshine
Pharmaceutical Co. shall be the People’s Republic of China. Sunshine will have the rights to sell, market and distribute the therapeutic agents in the territory as defined. Sunshine will have the right to utilize a third party for distribution
within the territory. It is not intended nor granted that the rights shall be sub-licensed by Sunshine to a third party. 
 Diligence Requirement:

 Sunshine shall use commercially reasonable efforts to diligently perform its obligations under a Development Program agreed by both parties and to
further develop and commercialize the Therapeutic Product(s). The Development Program details will be completed under a separate agreement. Breach of contract could be attained by Sunshine if certain milestones in the Development Program are not
achieved. Such a breach may result in revocation of the exclusive license granted by Epitomics to Sunshine Pharmaceutical Company pertaining to the use, distribution, manufacture and general commercialization of the agreed upon targeted Therapeutic
Products (anti-TNFalpha) or any other agreed upon targets. 
 Licensing Fee: 
 Upon signing of this agreement, Sunshine shall pay a one time licensing fee of *** to Epitomics. The fee will be paid in US dollars and wired via an agreed upon mechanism. 
 Development Funding & Responsibilities of each Participating Parties: 
  

	1)	Epitomics, Inc. will provide “Humanized Rabbit anti-TNFalpha monoclonal antibodies” to Sunshine Pharmaceutical Company. It is anticipated that the approximate delivery of
the humanized Rabbit anti-TNFalpha monoclonal antibodies to Sunshine will occur within nine (9) months from the signing of this agreement. Epitomics, Inc. will be solely responsible for the delivering of the “Humanized Rabbit anti-TNFalpha
monoclonal antibodies” and Sunshine Pharmaceuticals will cover the cost of humanization up to ***. In addition, Epitomics will provide 100 mg humanized antibodies. 

  

 2 

 REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN***. 
  

	2)	Sunshine Pharmaceutical Company shall be solely responsible for performing (and paying for) the following: 

  

	 	a.	Creating a Stable Cell line for the production of anti-TNFalpha monoclonal antibodies 

  

	 	b.	Performing appropriate animal studies on the anti-TNFalpha monoclonal antibodies 

  

	 	c.	Producing the anti-TNFalpha monoclonal antibodies in both quality and yield so as to “support” a Therapeutic grade product 

  

	 	d.	Develop and implement a strategy to get the anti-TNFalpha monoclonal antibodies into clinical trials within the Chinese Therapeutic market 

  

	 	e.	Will pay for the appropriate studies, licenses, production and documentation to support getting the anti-TNFalpha monoclonal antibodies through and “Approved and Released
Status” as a registered Therapeutic agent under an SFDA Approval status. Sunshine will have the rights to sell, market and distribute the therapeutic agents in the territory as defined. Sunshine will have the right to utilize a third party for
distribution within the territory. 

  

	 	f.	It is anticipated that Sunshine will fund and begin development of their responsibilities upon receipt of the “Humanized Rabbit anti-TNFalpha monoclonal antibodies” from
Epitomics, Inc. Failure for Sunshine to take pro-active and timely steps in the development and creation of the items listed above may be recognized as “breach” to this agreement. If a “breach” is determined by Epitomics, they
will communicate the “breach” formally in writing and Sunshine will have thirty (30) to rectify the situation. After thirty (30) days if the “breach” has not been resolved, Epitomics may terminate the agreement. If that decision
is reached, Epitomics, Inc. will formally notify Sunshine in writing regarding the decision to terminate the agreement. If termination occurs, the rights that have been granted Sunshine in the use, distribution, manufacture and all others regarding
the targeted therapeutics will terminate. If termination of this agreement occurs, Sunshine agrees to return all of Epitomics clones, antibodies, reagents, etc., that were used in connection with and /or for the development and commercialization of
the intended purpose of this agreement. 

  

 3 

 REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN***. 
  

	3)	Both parties are responsible for sending a detailed progress report on development of the Therapeutic Product. Such a report should be sent at least every six months.

 Royalty: 
 A *** royalty on the
net sales of the Therapeutics shall be paid by Sunshine to Epitomics. The royalty payments will be paid quarterly and made payable to Epitomics, Inc. in US dollars. The exact mechanism will be determined at a later date. 
 Intellectual Property: 
 Sunshine grants Epitomics the right to
use all intellectual properties generated during the development of the Therapeutic Product under this agreement. If Epitomics uses these intellectual properties for the development of the same Therapeutic Product outside of Sunshine’s
territory, Epitomics shall pay Sunshine *** royalty on the financial benefit including licenses and product sales. Any new developments or agents that are created due to Co-Development relationship, Sunshine will grant to Epitomics the “first
right of refusal” for the commercialization of such agents. It is anticipated if such development occurs, both parties will work in good faith to establish and create fair and equitable licensing terms on the newly created agents. Later
documentation and agreements should support this philosophy and mechanism. 
 Confidentiality: 
 The term “Confidential Information” shall mean the terms of this Agreement and any other information identified by Epitomics as being confidential information
of Epitomics, that is provided by Epitomics to Sunshine pursuant to this Agreement. This Agreement imposes no obligation upon Sunshine with respect to Confidential Information that: (a) was in Sunshine’ possession before receipt from Epitomics;
(b) is or becomes a matter of public knowledge or part of the public domain through no fault of Sunshine; (c) is rightfully received by Sunshine from a third party who was not obligated to keep such information confidential; (d) is independently
developed by Sunshine without reference to Confidential Information as evidenced by written documentation and by persons that had not had access to Confidential Information; or (e) is disclosed by Sunshine with Epitomics’s prior written
approval. Upon Epitomics’s request, Sunshine shall either return or destroy within ten (10) days of such request all records and copies of Confidential Information and provide written notice certifying the same to Epitomics. 
  

 4 

 REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN***. 
 Indemnification: 
  

	(a)	Sunshine shall indemnify Epitomics against any and all liability, loss, damages, cost and expenses, including, without limitation, reasonable attorneys’ fees, arising from any
claim, suit or proceeding arising out of breach of Sunshine’s confidentiality obligations hereunder or brought by any third party, solely to the extent that the claim, suit or proceeding is based upon a claim that the manufacture by Sunshine of
the Products delivered hereunder violates any issued patent or other intellectual property protection or contract. Epitomics shall promptly notify Sunshine in writing of any such claim or action and give Sunshine full information and assistance, at
Sunshine’s expense, in connection therewith. Sunshine has the sole right to control the defense of such claim or action. 

  

	(b)	Notwithstanding the foregoing, Sunshine has no liability for any claim, suit or proceeding based upon a claim that Confidential Information provided by Epitomics hereunder for such
Products infringes any third party intellectual property rights. Further, Sunshine has no liability to Epitomics for any claim of infringement to the extent such infringement is a result of (i) Epitomics’s or any third party’s use of a
Sunshine Product in combination with any items not supplied by Sunshine; and/or (ii) any modification of a Sunshine Product by Epitomics or any third party. 

  

	(c)	Sunshine shall indemnify Epitomics against any and all liability, damages, cost and expenses, including, without limitation, reasonable attorneys’ fees, finally awarded against
Epitomics based upon any claim, suit or proceeding brought by any third party, solely to the extent that the claim, suit or proceeding is based upon a claim that the Confidential Information provided by Sunshine hereunder (or the manufacture of the
Products that include such Confidential Information thereof) infringe any third party intellectual property rights. Epitomics shall promptly notify Sunshine in writing of any such claim or action and give Sunshine full information and assistance, at
Sunshine’s expense, in connection therewith. Sunshine shall have the sole right to control the defense of such claim. 

 Disclaimer:

 EXCEPT AS EXPRESSLY SET FORTH IN SECTION 3 HEREIN, NEITHER PARTY MAKES ANY WARRANTY, EXPRESS OR IMPLIED (INCLUDING, WITHOUT
LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE) WITH RESPECT TO THE CONFIDENTIAL INFORMATION OR THE PRODUCTS. SUNSHINE IS NOT LIABLE FOR ANY USE OF THE CONFIDENTIAL INFORMATION BY EPITOMICS, OR FOR ANY LOSS, CLAIM,
DAMAGE OR LIABILITY, OF ANY KIND OR NATURE, OTHER THAN AS EXPRESSLY STATED IN THIS AGREEMENT, WHICH MAY ARISE FROM OR IN CONNECTION WITH THIS AGREEMENT OR FROM THE USE, HANDLING OR STORAGE OF THE ANTIGENS OR RELATED MATERIALS BY EPITOMICS. EXCEPT AS
SET FORTH IN THIS AGREEMENT, EPITOMICS IS NOT LIABLE FOR ANY LOSS, CLAIM, DAMAGE OR LIABILITY OF ANY KIND OR NATURE, WHICH MAY ARISE FROM OR IN CONNECTION WITH THE USE, HANDLING OR STORAGE OF THE PRODUCTS BY SUNSHINE. 
  

 5 

 REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN***. 
 Limitation of Liability: 
 EXCEPT WITH RESPECT
TO INDEMNIFICATION OBLIGATIONS OF EACH PARTY PURSUANT TO THIS AGREEMENT, IN NO EVENT DOES EITHER PARTY HAVE ANY LIABILITY TO THE OTHER PARTY OR ANY OTHER THIRD PARTY FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL OR SPECIAL DAMAGES ARISING OUT OF THIS
AGREEMENT, INCLUDING WITHOUT LIMITATION, LOST OPPORTUNITY, LOST PROFITS, AND COSTS OF PROCUREMENT OF SUBSTITUTE GOODS, UNDER ANY CAUSE OR THEORY OF LIABILITY, AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THESE
LIMITATIONS APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY. EXCEPT WITH RESPECT TO INDEMNIFICATION OBLIGATIONS OF EACH PARTY, NEITHER PARTY’S LIABILITY UNDER THIS AGREEMENT SHALL EXCEED THE AMOUNT PAYABLE TO
EPITOMICS PURSUANT TO SECTION 2 OF THIS AGREEMENT. 
 Miscellaneous: 
  

	(a)	This Agreement is governed by and enforced according to the laws of the State of California without giving effect to its or any other jurisdiction’s conflict of laws
provisions. 

  

	(b)	In the event that either Party hereto is prevented from or delayed in the performance of any of its obligations hereunder by reason of acts of God, war, strikes, riots, storms,
fires or any other cause whatsoever beyond the reasonable control of the party, the party so prevented or delayed is excused from the performance of any such obligation to the extent and during the period of such prevention or delay.

  

	(c)	Neither Party to this Agreement may assign or transfer any rights or obligations arising from this Agreement without the prior written consent of the other. Any assignment in
violation of this Paragraph 11(c) shall be null and void. 

  

	(d)	Epitomics and Sunshine are independent contractors and may not be deemed to be partners, joint ventures or each other’s agents, and neither Party has the right to act on behalf
of the other except as is expressly set forth in this Agreement. 

  

	(e)	If any provision of this Agreement is finally held to be invalid, illegal or unenforceable by a court of competent jurisdiction, the remaining provisions hereof continue in full
force and effect. 

  

 6 

 REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN***. 
  

	(f)	This Agreement sets forth and constitutes the final and entire agreement between the Parties with respect to the subject matter hereof. All prior negotiations, understandings,
promises and agreements, oral or written, are superseded hereby. 

  

	(g)	This Agreement may not be amended or modified except by a written instrument signed by authorized representatives of both Parties. 

  

	(h)	All notices required or permitted to be given under this Agreement must be in writing and must be sent either by; (i) prepaid registered or certified mail (return receipt
requested); (ii) prepaid overnight courier service; or (iii) by facsimile (and promptly confirmed by such registered or certified mail or overnight courier service) to the address of the recipient Party set forth below, or at such other address as
may from time to time be furnished by similar written notice by such Party. Any such communication shall be deemed to have been given (i) when delivered, if personally delivered or sent by telecopier on a business day, (ii) on the business day after
dispatch, if sent by nationally-recognized overnight courier, and (iii) on the third business day following the date of mailing, if sent by mail. It is understood and agreed that this Section is not intended to govern the day-to-day business
communications necessary between the Parties in performing their duties, in due course, under the terms of this Agreement. 

 Notices to
Sunshine Pharmaceutical must be addressed to: 
 13th Floor, Tower B, Grand Place, 
 5
Huizhong Road, Chaoyang District, Beijing 100101 
 Tel: +86-10-8489 2211 
 Fax: +86 10 8489 2951 
 Attu: Dr. Jing Lou 
 Notices to Epitomics must be addressed to: 
 Epitomics, Inc. 
 863 Mitten Road, Suite 103 
 Burlingame, CA 94010 
 Fax: 01-650-583-6680 
 Attn: Dr. Guo-Liang Yu 
  

	(i)	The headings of the sections and subsections of this Agreement have been added for the convenience of the Parties and may not be deemed a part hereof. 

  

	(j)	Any delay in enforcing a party’s rights under this Agreement or any waiver as to a particular default or other matter does not constitute a waiver of a party’s right to
the future enforcement of its rights under this Agreement. 

  

 7 

 REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN***. 
  

	(k)	Each Party warrants that it has the right to enter into this Agreement, and that this Agreement is a legal and valid obligation binding upon such party and enforceable in accordance
with its terms. 

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their duly authorized
representatives. 
  

							
	SUNSHINE PHARMCETICAL Co. Ltd	 	EPITOMICS, INC.
				
	By	 	 /s/ Jing Lou
	 	By:	 	Guoliang Yu
			
	JING LOU	 		 	 /s/ Guoliang Yu

		
	Printed Name	 	Printed Name
		
	CEO      3/2/2006	 	CEO      3/4/2006
	Title	 	Date Signed	 	Title	 	Date Signed

  

 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00116-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00116-of-00352.parquet"}]]